TheraRadar
Clinical-Stage Companies / Laboratorio Elea Phoenix

Laboratorio Elea Phoenix

Pre-Approval PRO BETA
🟡

Slowing Activity

No new clinical trials started in 1-2 years. Monitor for changes in pipeline strategy. Last trial started: 11/28/2024

17
Total Trials
5
Phase 3
8
Phase 2
3
Recruiting
145
Score

Pipeline by Phase

Phase 3
5
Phase 2
8
Phase 1
2

Therapeutic Focus

Neuroblastoma COVID-19 Drug Treatment Healthy Parkinson Disease Non Small Cell Lung Cancer Metastatic

Clinical Trials (17)

NCT05668650 Phase 3 RECRUITING

Double-blind Study to Evaluate the PK, Efficacy, Safety and Immunogenicity of MB12 Versus Keytruda® in Stage IV NSCLC

Started: 8/15/2023

NCT04897516 Phase 3 RECRUITING

Shorter Benznidazole Regimens Compared to the Standard Regimen for Chagas Disease

Started: 7/28/2021

NCT04560881 Phase 3 COMPLETED

Clinical Trial to Evaluate the Efficacy, Immunogenicity and Safety of the Inactivated SARS-CoV-2 Vaccine (COVID-19)

Started: 9/16/2020

NCT03668054 Phase 3 COMPLETED

Safety and Clinical Effectiveness of Intravitreal Bevacizumab (Lumiere®) in Patients With Wet Age-related Macular Degeneration (Wet AMD)

Started: 2/7/2017

NCT06629389 Phase 2 RECRUITING

Clinical Trial with Cannabidiol (Kanbis®) for Parkinson Disease Symptoms

Started: 11/28/2024

NCT02998983 Phase 2 COMPLETED

Racotumomab in Patients With High-risk Neuroblastoma

Started: 11/1/2016

NCT04381884 Phase 2 COMPLETED

Ivermectin Effect on SARS-CoV-2 Replication in Patients With COVID-19

Started: 5/18/2020

NCT01623206 Phase 2 COMPLETED

Desmopressin (DDAVP) in Patients With Colorectal Cancer and Rectal Bleeding

Started: 4/1/2013

NCT01639625 Phase 2 COMPLETED

Concurrent Treatment of Squamous Cell Carcinoma or Adenocarcinoma of the Cervix With CIGB-300 for Local Application

Started: 5/1/2011

NCT01606072 Phase 2 COMPLETED

Perioperative Use of Desmopressin (DDAVP) in Breast Cancer

Started: 11/1/2011

NCT01639638 Phase 2 TERMINATED

Recurrent and Nonrecurrent Condyloma Treatment

Started: 6/1/2010

NCT01240447 Phase 2 COMPLETED

Immunotherapy With Racotumomab Versus Support Treatment in Advanced Non-small Cell Lung Cancer Patients

Started: 9/1/2009

NCT02583464 Phase 1 COMPLETED

Bioequivalence Study of Two Formulations With the Association of Tenofovir 300 mg and Emtricitabine 200 mg.

Started: 9/1/2014

NCT01598454 Phase 1 COMPLETED

Use of Racotumomab in Patients With Pediatric Tumors Expressing N-glycolylated Gangliosides

Started: 2/1/2011

NCT04355936 Phase 4 COMPLETED

Telmisartan for Treatment of COVID-19 Patients

Started: 5/19/2020

NCT03317236 Phase 4 COMPLETED

Bioequivalence Study of Two Extended Release Formulations Containing 50 mg of Quetiapine.

Started: 3/13/2017

NCT03309566 Phase 4 COMPLETED

Bioequivalence Study of Two Formulatiosns With the Asscociaton of Efavirenz, Emtricitabine and Tenofovir

Started: 9/4/2016

Drug Candidates

Cannabidiol 100 mg/ml cannabidiol 300 mg/ml Cannabidiol 400 mg/ml Placebo Pembrolizumab Pembrolizumab biosimilar Short regimen of benznidazole Short treatment with benznidazole Standard treatment with benznidazole Racotumomab
Activity Status: Slowing
Last Trial Started: 11/28/2024
Last Trial Ended: 11/1/2022
Trials (12 months): 0
Completed Trials: 13
Data sourced from ClinicalTrials.gov. This company has no FDA-approved drugs.